Aslan Pharmaceuticals
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 35
- Market Cap
- $1.6M
- Introduction
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for...
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05865041
- Locations
- 🇺🇸
1 Site, Webster, Texas, United States
🇺🇸2 Sites, San Antonio, Texas, United States
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT05694884
- Locations
- 🇨🇦
ASLAN Investigative Site, Toronto, Ontario, Canada
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT05158023
- Locations
- 🇺🇸
Skin Care Physicians of Georgia, Macon, Georgia, United States
🇺🇸Dermatology Treatment and Research Center, Dallas, Texas, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT04090229
- Locations
- 🇸🇬
National Skin Centre, Singapore, Singapore
🇺🇸Center for Dermatology Clinical Research, INC, Fremont, California, United States
🇦🇺Skin Health Institute, Inc., Carlton, Victoria, Australia
Study of ASLAN004 in Healthy Subjects
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT03721263
- Locations
- 🇸🇬
CGH Clinical Trials & Research Unit, Singapore, Singapore
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03451084
- Locations
- 🇸🇬
3 Sites, Singapore, Singapore
🇦🇺1 Site, Adelaide, South Australia, Australia
Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT03368846
- Locations
- 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03231176
- Locations
- 🇨🇳
No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China
🇨🇳There is 22 sites located in other cities of China, including Nanjing, Nanjing, China
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- ASLAN Pharmaceuticals
- Registration Number
- NCT03129074
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03130790
- Locations
- 🇰🇷
11 Sites, Seoul, Korea, Republic of
🇹🇭1 Site, Pathum Thani, Thailand
🇲🇾2 Sites, Kuala Lumpur, Malaysia